Pfizer's GLP-1 Drug Xianweiying Wins China Approval for Long-Term Weight Management
Shanghai: China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting competition in a market analysts expect to be worth billions in coming years.
The injection belongs to the class of GLP-1 receptor agonist drugs sold locally by drugmakers such as Novo Nordisk , Eli Lilly, and Innovent Biologics.
"This marks a breakthrough in field of weight management," Sciwind Biosciences, from which Pfizer licensed mainland China commercialisation rights in February, said on its website.
Sales of Novo's Wegovy on Alibaba's Tmall e-commerce platform and JD.com were 260 million yuan ($38 million) in 2025, against 416 million ($61 million) for Innovent's Xinermei, investment bank Jefferies said in a note.
In February, Pfizer licensed the mainland China commercialisation rights for Xianweiying, also known as ecnoglutide, from Sciwind, based in the eastern city of Hangzhou.
That deal was "an important first step to advance Pfizer's global strategy in the metabolic field in China", Sciwind said in a previous statement. Ecnoglutide is also approved in China as a treatment for Type II diabetes. A Pfizer spokesperson did not immediately respond to a request for comment on pricing and a China launch date.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.